Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.

Oncotarget - 1 Nov 2016

Pradhan Shrikant, Mahajan Divyank, Kaur Prabhjot, Pandey Namita, Sharma Chandresh, Srivastava Tapasya

Abstract excerpt

Non-small cell lung cancer (NSCLC), comprising 85% of lung cancer cases, has been associated with resistance to chemo/radiotherapy. The hypoxic tumor micro-environment, where insufficient vasculature results in poor drug penetrance and sub-optimal chemotherapy in the tumor interiors contributes heavily to this resistance. Additionally, epigenetic changes in tumorigenic cells also change their response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cell Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Histone Deacetylase Inhibitors

Share to Hydroxylamines

Share to Hypoxia-Inducible Factor 1, alpha Subunit

Share to Quinolines

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 27708247
DOI: 10.18632/oncotarget.12378
PMCID: PMC5342127

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.PMID 27708247Read ↗

Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.Semantic proximity Read ↗

Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancerSemantic proximity Read ↗

miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP)Semantic proximity Read ↗

SIRT3 increases cisplatin sensitivity of small-cell lung cancer through apoptosis.Semantic proximity Read ↗

Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.Semantic proximity Read ↗

Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.Semantic proximity Read ↗

Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive modelSemantic proximity Read ↗

Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.Semantic proximity Read ↗

Low-Dose Fractionated Radiation Potentiates the Effects of Cisplatin Independent of the Hyper-Radiation Sensitivity in Human Lung Cancer CellsSemantic proximity Read ↗

Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.Semantic proximity Read ↗

Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell LineSemantic proximity Read ↗

miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.